{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:19:53Z","timestamp":1788182393590,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Staff Fund at YNHH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01052-4","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T03:16:58Z","timestamp":1723778218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Providers\u2019 knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study"],"prefix":"10.1186","volume":"21","author":[{"given":"Katherine","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Minahan-Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma T.","family":"Biegacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"issue":"26","key":"1052_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine\u2014United States, January 2019\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7226a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1052_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jat\/bkac049","volume":"46","author":"SL Kacinko","year":"2022","unstructured":"Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework. J Anal Toxicol. 2022;46(8):911\u20137. https:\/\/doi.org\/10.1093\/jat\/bkac049.","journal-title":"J Anal Toxicol"},{"key":"1052_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36864","author":"S Ayub","year":"2023","unstructured":"Ayub S, Parnia S, Poddar K, et al. Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.36864.","journal-title":"Cureus"},{"issue":"8","key":"1052_CR4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136. https:\/\/doi.org\/10.2105\/AJPH.2022.306881.","journal-title":"Am J Public Health"},{"issue":"1","key":"1052_CR5","first-page":"43","volume":"34","author":"EA Gardner","year":"2022","unstructured":"Gardner EA, McGrath SA, Dowling D, Bai D. The opioid crisis: prevalence and markets of opioids. Forensic Sci Rev. 2022;34(1):43\u201370.","journal-title":"Forensic Sci Rev"},{"key":"1052_CR6","unstructured":"Wide-Ranging Online Data for Epidemiologic Research (WONDER). CDC, National Center for Health Statistics; 2021. http:\/\/wonder.cdc.gov"},{"key":"1052_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.010.","journal-title":"Int J Drug Policy"},{"key":"1052_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Col\u00f3n","year":"2014","unstructured":"Ruiz-Col\u00f3n K, Chavez-Arias C, D\u00edaz-Alcal\u00e1 JE, Mart\u00ednez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1\u20138. https:\/\/doi.org\/10.1016\/j.forsciint.2014.03.015.","journal-title":"Forensic Sci Int"},{"key":"1052_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/add.16388","author":"KL Sue","year":"2023","unstructured":"Sue KL, Hawk K. Clinical considerations for the management of xylazine overdoses and xylazine-related wounds. Addiction. 2023. https:\/\/doi.org\/10.1111\/add.16388.","journal-title":"Addiction"},{"issue":"7","key":"1052_CR10","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. 2023;240(7):1561\u201371. https:\/\/doi.org\/10.1007\/s00213-023-06390-y.","journal-title":"Psychopharmacology"},{"key":"1052_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001198","author":"A Dowton","year":"2023","unstructured":"Dowton A, Doernberg M, Heiman E, et al. Recognition and treatment of wounds in persons using xylazine: a case report from New Haven, Connecticut. J Addict Med. 2023. https:\/\/doi.org\/10.1097\/ADM.0000000000001198.","journal-title":"J Addict Med"},{"issue":"4","key":"1052_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/NUR.0000000000000758","volume":"37","author":"PA O\u2019Malley","year":"2023","unstructured":"O\u2019Malley PA. Rising xylazine drug abuse in humans: a deep and lingering high with wounds, amputations, and death. Clin Nurse Spec. 2023;37(4):164\u20135. https:\/\/doi.org\/10.1097\/NUR.0000000000000758.","journal-title":"Clin Nurse Spec"},{"key":"1052_CR13","unstructured":"Pennsylvania Department of Health. Xylazine and Wound Care for Healthcare Providers. 2023. https:\/\/www.health.pa.gov\/topics\/Documents\/Opioids\/Xylazine%20Provider%20Info.pdf"},{"key":"1052_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001245","author":"R McFadden","year":"2023","unstructured":"McFadden R, Wallace-Keeshen S, Petrillo Straub K, et al. Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia. J Addict Med. 2023. https:\/\/doi.org\/10.1097\/ADM.0000000000001245.","journal-title":"J Addict Med"},{"key":"1052_CR15","unstructured":"Gupta R. Biden-\u2060Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. 2023. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/04\/12\/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states\/"},{"issue":"1","key":"1052_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1747-597X-6-7","volume":"6","author":"RA Torruella","year":"2011","unstructured":"Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy. 2011;6(1):7. https:\/\/doi.org\/10.1186\/1747-597X-6-7.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"1052_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","volume":"89","author":"JC Reyes","year":"2012","unstructured":"Reyes JC, Negr\u00f3n JL, Col\u00f3n HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519\u201326. https:\/\/doi.org\/10.1007\/s11524-011-9662-6.","journal-title":"J Urban Health"},{"key":"1052_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001132","author":"AC Holt","year":"2023","unstructured":"Holt AC, Schwope DM, Le K, Schrecker JP, Heltsley R. Widespread distribution of xylazine detected throughout the United States in healthcare patient samples. J Addict Med. 2023. https:\/\/doi.org\/10.1097\/ADM.0000000000001132.","journal-title":"J Addict Med"},{"key":"1052_CR19","unstructured":"DEA. PUBLIC SAFETY ALERT: DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine. https:\/\/www.dea.gov\/alert\/dea-reports-widespread-threat-fentanyl-mixed-xylazine"},{"key":"1052_CR20","unstructured":"CTDPH. Connecticut Department of Public Health Drug Overdose Monthly Report. https:\/\/portal.ct.gov\/-\/media\/DPH\/Injury-and-Violence-Prevention\/Opioid-Overdose-Data\/Monthly-Death-Reports\/2019-March-2023_Drug-Overdose-Deaths-Monthly-Report_Connecticut_updated-on-4-18-2023_Final.pdf"},{"key":"1052_CR21","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104154.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1052_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0955-3959(03)00075-6","volume":"14","author":"P Goddard","year":"2003","unstructured":"Goddard P. Changing attitudes towards harm reduction among treatment professionals: a report from the American Midwest. Int J Drug Policy. 2003;14(3):257\u201360. https:\/\/doi.org\/10.1016\/S0955-3959(03)00075-6.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1052_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"6","key":"1052_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/15563658108990293","volume":"18","author":"AG Gallanosa","year":"1981","unstructured":"Gallanosa AG, Spyker DA, Shipe JR, Morris DL. Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants. Clin Toxicol. 1981;18(6):663\u201378. https:\/\/doi.org\/10.3109\/15563658108990293.","journal-title":"Clin Toxicol"},{"issue":"12","key":"1052_CR25","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/add.15111","volume":"115","author":"HE Jones","year":"2020","unstructured":"Jones HE, Harris RJ, Downing BC, et al. Estimating the prevalence of problem drug use from drug-related mortality data. Addiction. 2020;115(12):2393\u2013404. https:\/\/doi.org\/10.1111\/add.15111.","journal-title":"Addiction"},{"issue":"3","key":"1052_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.drugpo.2005.02.010","volume":"17","author":"MG Law","year":"2006","unstructured":"Law MG, Degenhardt L, McKetin R. Methods estimating the prevalence of problem drug use. Int J Drug Policy. 2006;17(3):154\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2005.02.010.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1052_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53. https:\/\/doi.org\/10.1186\/s12954-020-00399-8.","journal-title":"Harm Reduct J"},{"key":"1052_CR28","doi-asserted-by":"publisher","first-page":"108589","DOI":"10.1016\/j.drugalcdep.2021.108589","volume":"221","author":"C Fong","year":"2021","unstructured":"Fong C, Mateu-Gelabert P, Ciervo C, et al. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug Alcohol Depend. 2021;221:108589. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108589.","journal-title":"Drug Alcohol Depend"},{"key":"1052_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.037.","journal-title":"Drug Alcohol Depend"},{"key":"1052_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","volume":"57","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104\u201310. https:\/\/doi.org\/10.1016\/j.drugpo.2018.04.004.","journal-title":"Int J Drug Policy"},{"key":"1052_CR31","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.drugpo.2021.103112","volume":"93","author":"BE Meyerson","year":"2021","unstructured":"Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB. I don\u2019t even want to go to the doctor when I get sick now: Healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103112.","journal-title":"Int J Drug Policy"},{"key":"1052_CR32","doi-asserted-by":"publisher","first-page":"100496","DOI":"10.1016\/j.abrep.2023.100496","volume":"17","author":"S Nolen","year":"2023","unstructured":"Nolen S, Wilson T, Jacka BP, Li Y, Beaudoin FL, Marshall BDL. Prevalence and correlates of experiencing drug-related discrimination among people who use drugs presenting at emergency department at high risk of opioid overdose. Addict Behav Rep. 2023;17:100496. https:\/\/doi.org\/10.1016\/j.abrep.2023.100496.","journal-title":"Addict Behav Rep"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01052-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01052-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01052-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T03:18:52Z","timestamp":1723778332000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01052-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01052-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yale\u2019s Institutional Review Board deemed this study exempt from human subjects review. All potential participants in the quantitative phase were provided with information about this study at the beginning of the survey and completion of the survey was accepted as consent to participate. Prior to interviews in the qualitative phase, participants were provided an information sheet and consent form via email; these forms described the purpose and procedures of the study, their rights as participants, confidentiality measures, and potential risk. Participants had the option to have the documents verbally reviewed with them by a member of the study team and were given the opportunity to ask questions. Verbal consent to be interviewed and for recording the interview was obtained prior to beginning the qualitative phase and all participants were advised on their right to terminate participation at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}